FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Thursday

 

Research findings may pave way for innovative treatments of MS








































Image Source: JONLIEFFMD

Inhibition of the protein kinase CK2 prevents the development of auto-aggressive T cells

Researchers at the Research Center for Immunotherapy (FZI) and the Focus Program Translational Neurosciences (FTN) of Johannes Gutenberg University Mainz (JGU) have identified a new mechanism that is involved in the development of autoimmune diseases. On the basis of this new insight, it may prove possible to create innovative treatments for disorders such as multiple sclerosis (MS). The members of the research team headed by Professor Tobias Bopp at the Institute of Immunology at the Mainz University Medical Center and Professor Frauke Zipp at the Department of Neurology, were able to demonstrate that it is possible to influence the development and functioning of regulatory T cells, also known as Tregs, and T helper 17 (TH17) cells by means of inhibition of the protein kinase CK2. It would seem that many of the devastating effects of autoimmune disorders are attributable to TH17 cells.
Among other factors, the relative levels of these two types of cells determine whether or not an autoimmune disorder develops. For this reason, the researchers aimed to create an imbalance in favor of the Tregs. They were able to achieve this by inhibiting the development of the auto-aggressive TH17 cells through a blockade of CK2 and the simultaneous promotion of the synthesis of Tregs. The efficacy of this approach has already been impressively confirmed in pre-clinical models. The results of the Mainz study "Protein kinase CK2 governs the molecular decision between encephalitogenic TH17 cell and Treg cell development" are available in the online version of the leading specialist journal Proceedings of the National Academy of Sciences (PNAS).

The human immune system is extremely efficient in recognizing intruders that could be potentially damaging to health. A sub-group of white blood cells, the so-called T cells, identify invading pathogens on the basis of their proteins and normally orchestrate an appropriate qualitative and quantitative defensive immune reaction. This neutralizes the exogenous invaders in a targeted manner and eliminates them. In rare cases, this type of defensive reaction may culminate in an exaggerated immune response. It is to prevent exactly such excessive immune reactions that regulatory T-cells, the so-called Tregs, have evolved over time.

In healthy individuals, these Tregs serve to maintain immunological tolerance. They protect harmless antigens such as foreign proteins in food that might otherwise trigger an endogenous defensive reaction, as well as the body's own structures in the case of inappropriately activated immune responses. They thus also prevent the development of allergies and autoimmune disorders, including multiple sclerosis (MS).

A sub-population of T helper cells, the so called Interleukin-(IL)17 producing TH17 cells, plays a major role in the development of MS. In healthy individuals, these TH17 cells are responsible for the control of infecting bacteria and fungi. However, TH17 cells also have a potentially negative, auto-aggressive effect in that they can be responsible for the destructive processes that occur in the presence of inflammations and also in many autoimmune conditions.

The researchers at the Mainz University Medical Center now discovered that not only the ratio of Tregs to TH17 cells decisively determines whether or not an autoimmune disorder develops but also, and more importantly, that pharmacological inhibition of CK2 tips the balance of the two cell types towards Tregs.

Protein kinases are the second largest family of proteins present in higher cells. They modify other proteins and thus change the biological properties of these proteins. The researchers were able to show that inhibition of the protein kinase CK2 results in a blockade of exactly those signal pathways required by TH17 cells in order to evolve. On a molecular level, the inhibition of the protein kinase CK2 leads to inhibition of the signal pathways mediated by the cytokines interleukin-6, interleukin-21, and interleukin-23 as well as those that regulate gene expression through the transcription factor STAT3. This leads to the expression of another transcription factor called forkhead-box protein P3 (FOXP3), which in its turn controls the development and functioning of Tregs by means of genetic regulation. Thus, the auto-aggressive TH17 cells that are actually involved in the generation of autoimmune diseases are 'deprogrammed' in cells which protect endogenous structures, hence preventing the onset of these disorders.


Story Source: The above story is based on materials provided by NEWS-MEDICAL
Note: Materials may be edited for content and length


Go to Newer News Go to Older News